Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Debt: 2020-2021

Historic Non-Current Debt for RedHill Biopharma (RDHL) over the last 2 years, with Dec 2021 value amounting to $83.6 million.

  • RedHill Biopharma's Non-Current Debt rose 2.74% to $83.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $83.6 million, marking a year-over-year increase of 2.74%. This contributed to the annual value of $83.6 million for FY2021, which is 2.74% up from last year.
  • As of FY2021, RedHill Biopharma's Non-Current Debt stood at $83.6 million, which was up 2.74% from $81.4 million recorded in FY2020.
  • In the past 5 years, RedHill Biopharma's Non-Current Debt registered a high of $83.6 million during FY2021, and its lowest value of $81.4 million during FY2020.
  • Moreover, its 2-year median value for Non-Current Debt was $82.5 million (2020), whereas its average is $82.5 million.
  • Data for RedHill Biopharma's Non-Current Debt shows a peak YoY grew of 2.74% (in 2021) over the last 5 years.
  • Yearly analysis of 2 years shows RedHill Biopharma's Non-Current Debt stood at $81.4 million in 2020, then grew by 2.74% to $83.6 million in 2021.